CytoDyn Inc (OTCMKTS:CYDY) Stock Comes Back Strongly: Jumped 50% Last Week

September 20, 2021

Late stage biotech firm CytoDyn Inc (OTCMKTS:CYDY) seemed to have come into the radars of investors in a big way last week. This past Friday, the stock managed to end the week with gains of 22% and that took its gains for the whole week to a handsome 49%. While the stock may be back in focus, it is also necessary to note that there was no news about the…

Read More >>

CytoDyn Inc (OTCMKTS:CYDY) Administers Leronlimab Drug to First Patient in Major Phase 3 Covid-19 Trial

September 15, 2021

CytoDyn Inc (OTCMKTS:CYDY) has made a statement regarding its treatment of the first patient with its much-touted about drug candidate leronlimab (Vyrologix or PRO 140), in a crucial Phase 3 Covid-19 trial in Brazil. The treatment is for patients with severe symptoms. After the enrolment of 245 patients (40% of the total number in the trial), an interim analysis will be conducted after 28 days. The trial is being conducted…

Read More >>

CytoDyn Inc (CYDY) Stock Jumps To One Month High On Unusual Volume

September 14, 2021

Late stage biotech firm CytoDyn Inc (OTCMKTS:CYDY) came back to life on the markets on Monday and its stock ended up as one of the notable gainers, as it soared by as much as 22%. The rally in the stock came about after the company made a key announcement with regards to a presentation that is going to be made by the top executives at CytoDyn on Wednesday, September 15,…

Read More >>

CytoDyn Inc. (OTCMKTS:CYDY) Stock Sees Buying Interest On Value Buying

September 13, 2021

CytoDyn Inc. (OTCMKTS:CYDY) jumped 8% after announcing the treatment of a first p[atient with its lead drug product leronlimab in a crucial third phase COVID-19 study in Brazil for those with severe symptoms. The biotech company said it would conduct a preliminary analysis in 28 days after enrolment of 245 patients representing around 40% of the number of subjects the company intends to enroll in the study. CytoDyn had previously…

Read More >>

CytoDyn (OTCMKTS:CYDY) Announces Treatment Of The First Patient In Its Pivotal Phase 3 Covid-19 Trial In Brazil

September 10, 2021

Late-stage biotechnology company, CytoDyn (OTCMKTS:CYDY), which is developing  Inc leronlimab, having potential for myriad  therapeutic indications, on September 9, 2021 announced treatment of the first patient in Phase 3 COVID-19 trial in Brazil for patients having severe symptoms. Interim analysis would be done in 28 days after enrolling 245 patients, 40% of the total patients enrolled in the trial. The phase 3 trial is being done for serious covid patients…

Read More >>

CytoDyn Inc (CYDY) Stock Continues to Hit New Lows: Where is the Bottom?

September 3, 2021

The CytoDyn Inc (OTCMKTS:CYDY) stock was back in focus yesterday after the Board of Directors at the company sent out a key statement. The statement was in relation to the court order delivered yesterday a District Court Judge about the lawsuit that had been filed by CytoDyn against an activist investor group headed by Bruce Patterson and Paul Rosenbaum. However, the statement from the Board of Directors did not have…

Read More >>

CytoDyn Inc (OTCMKTS:CYDY) Stock Attempts To Bounce Back: Will it Sustain?

August 16, 2021

The presence of activist investors in a company can often lead to a fair degree of uncertainty for investors but last week the CytoDyn Inc (OTCMKTS:CYDY) stock actually performed strongly. There was no news about the biopharmaceutical company last week but the stock performed strongly. On Friday, it jumped by 5% and ended the week with gains of as much as 12.50%. In this situation, it might be a good…

Read More >>

CytoDyn Inc. (OTCMKTS:CYDY) Stock Continues to Struggle At Lower Levels: Now What?

August 11, 2021

CytoDyn Inc. (OTCMKTS:CYDY) is down 6% in a week after announcing approval from Brazilian regulatory agency ANVISA for its previously submitted clinical study protocol to start patient recruitment in the CD17 study for severe coronavirus patients. The company will, in collaboration, conduct the trial with Academic Research Organisation Albert Einstein Israelite Hospital. The study will produce requisite data needed by ANVISA to consider leronlimab’s availability to patients with severe CPVID-19…

Read More >>

CytoDyn Inc (OTCMKTS:CYDY) Stock Slips To A New Low: Should You Panic?

August 5, 2021

Late-stage biotechnology firm, CytoDyn Inc (OTCMKTS:CYDY) on August 3, 2021, announced that director nominations done by an activist group led by Bruce Patterson and Paul Rosenbaum were invalid. The Group attempted on nominating five director candidates for taking over control of the firm’s six-member Board of Directors. CytoDyn’s bylaws have a standard “advance notice bylaw” for protecting shareholders, requiring disclosures through shareholder nomination as well as nominees for providing all…

Read More >>

CytoDyn Inc (OTCMKTS:CYDY) Stock Resumes Selling Pressure: A Good Buy Now?

August 3, 2021

Late stage biotech firm CytoDyn Inc (OTCMKTS:CYDY) was in the middle of a heavy selloff yesterday in the markets and saw its stock slump by as much as 9%. The selloff in the stock was possibly triggered by an announcement from CytoDyn with regards to the director nominations that had been submitted by an activist investor group. The company announced that the nominations from the activist investors group, headed by…

Read More >>